(Hypertension. 1995;25:620-625.)
© 1995 American Heart Association, Inc.
Articles |
Effectiveness of Enalapril Versus Nifedipine to Antagonize Blood Pressure and the Renal Response to Endothelin in Humans
From the Department of Nephrology and Hypertension, University Hospital Utrecht (the Netherlands).
Abstract Endothelin-1 infusion into humans to obtain pathophysiological plasma levels causes mild hypertension, strong renal vasoconstriction, and sodium retention. We studied whether oral use of the angiotensin-converting enzyme inhibitor enalapril (20 mg BID) or the calcium channel blocker nifedipine (60 mg OD) could attenuate these effects of endothelin-1 (2.5 ng/kg per minute for 90 minutes) in six healthy volunteers. Endothelin infusion alone increased plasma endothelin from 3.0±0.3 to 8.8±1.0 pmol/L (P<.05). Blood pressure rose by approximately 6 mm Hg (P<.05). Renal function changes were relatively large: Renal blood flow decreased from 941±76 to 729±118 mL/min (P<.05) and glomerular filtration rate from 105±9 to 92±10 mL/min (P<.05); renal vascular resistance increased from 101±7 to 152±20 mm Hg · min/L (P<.05); and sodium excretion decreased from 158±54 to 86±27 µmol/min (P<.05). Enalapril treatment reduced blood pressure from 94±2 to 87±3 mm Hg (P<.05) and prevented the hypertensive response to endothelin. By contrast, despite renal predilatation, endothelin reduced renal blood flow strongly (from 1063±127 to 763±100 mL/min, P<.05), although maximal renal vascular resistance was numerically lower (124±11 mm Hg · min/L) than during endothelin alone (P<.05). Glomerular filtration rate fell from 118±11 to 108±11 mL/min (P<.05). Enalapril did not alter the antinatriuretic effect of endothelin. Nifedipine did not affect blood pressure but prevented the increase caused by endothelin. The endothelin-induced fall in renal blood flow (from 1084±100 to 888±65 mL/min, P<.05) was less than during endothelin infusion alone (P<.05), and maximal renal vascular resistance (111±7 mm Hg · min/L) was lower than in both other experiments (P<.05), whereas glomerular filtration rate was maintained. Nifedipine increased basal sodium excretion (P<.05), which compensated for the decrease observed during superimposed endothelin infusion. In conclusion, both enalapril and nifedipine can counteract the hypertensive effect of endothelin, but nifedipine is more effective in antagonizing the renal effects of endothelin.
Key Words: endothelins • angiotensin-converting enzyme inhibitors • calcium channel blockers • renal circulation
This article has been cited by other articles:
 |
|
 |
|
  J. L. Tycho Vuurmans, P. Boer, and H. A. Koomans Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2742 - 2746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Vuurmans, H. Koomans, and P. Boer Is coating of tubing required when endothelin-1 is infused intravenously? Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1677 - 1678. [Full Text] [PDF]
|
|
|
|
|
|
T. Vuurmans, H. Koomans, and P. Boer Is coating of tubing required when endothelin-1 is infused intravenously? Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1677 - 1678. [Full Text]
|
|
|
|
 |
|
 T. J.L. Vuurmans, P. Boer, and H. A. Koomans Effects of Endothelin-1 and Endothelin-1 Receptor Blockade on Cardiac Output, Aortic Pressure, and Pulse Wave Velocity in Humans Hypertension, June 1, 2003; 41(6): 1253 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. H. HONING, M. L. HIJMERING, D. E. BALLARD, Y. P. YANG, R. J. PADLEY, P. J. MORRISON, and T. J. RABELINK Selective ETA Receptor Antagonism with ABT-627 Attenuates All Renal Effects of Endothelin in Humans J. Am. Soc. Nephrol., August 1, 2000; 11(8): 1498 - 1504. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. C. Verhaar, M. L.H. Honing, T. van Dam, M. Zwart, H. A. Koomans, J. J.P. Kastelein, and T. J. Rabelink Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids Cardiovasc Res, June 1, 1999; 42(3): 752 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Rossi, E. Zilli, A. C. Pessina, K. A.H. Kaasjager, H. A. Koomans, and T. J. Rabelink Renal Effects of Endothelin-1 in Essential Hypertension • Response Hypertension, February 1, 1998; 31(2): 721 - 722. [Full Text]
|
|
|
|
|
|
K. A. H. Kaasjager, H. A. Koomans, and T. J. Rabelink Endothelin-1–Induced Vasopressor Responses in Essential Hypertension Hypertension, July 1, 1997; 30(1): 15 - 21. [Abstract] [Full Text]
|
|
|
|
|
|
E. S.G. Stroes, T. F. Luscher, F. G. de Groot, H. A. Koomans, and T. J. Rabelink Cyclosporin A Increases Nitric Oxide Activity In Vivo Hypertension, February 1, 1997; 29(2): 570 - 575. [Abstract] [Full Text]
|
|
|
|
|
|
S.-i. Ando, M. A. Rahman, G. C. Butler, B. L. Senn, and J. S. Floras Comparison of Candoxatril and Atrial Natriuretic Factor in Healthy Men : Effects on Hemodynamics, Sympathetic Activity, Heart Rate Variability, and Endothelin Hypertension, December 1, 1995; 26(6): 1160 - 1166. [Abstract] [Full Text]
|
|